Early Detection, Diagnosis, Prognosis

Home Research For Researchers Research Digest Early Detection, Diagnosis, Prognosis

Publications investigating improved diagnostic markers or imaging techniques as well as markers that indicate treatment response or influence treatment decisions.


Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm
Pancreatic Cancer Action Network Latest News blog article: New Study Identifies Test to Diagnose Benign Pancreatic Cysts

  • Journal: Journal of the American College of Surgeons
  • Institution(s): Indiana University School of Medicine, Indianapolis, IN
  • Corresponding author(s): C. Max Schmidt
  • Pancreatic Cancer Action Network-affiliated author: C. Max Schmidt, MD, PhD, MBA, FACS: recipient, 2003 Career Development Award
  • Major finding: Although VEGF-A alone is a highly accurate test for serous cystic neoplasms (SCN), the combination of VEGF-A with CEA approaches the gold standard for pathologic diagnosis, importantly avoiding false positives. Patients with a positive test indicating benign SCN can be spared a high-risk surgical pancreatic resection.

 
 
Pancreatic Cysts -- Part 1: Using the American Gastroenterological Association Guidelines for the Management of Pancreatic Cysts-A Practical Approach

  • Journal: Pancreas
  • Institution(s): University of Michigan Medical School, Ann Arbor, MI
  • Corresponding author(s): James Scheiman
  • Major finding: The recent publication of evidence-based guidelines by the American Gastroenterological Association for the management of the incidental pancreatic cyst has stimulated considerable discussion among clinicians and researchers. A practical approach to using these guidelines in daily clinical practice is discussed, emphasizing that an individualized approach is often required for this diverse and common clinical problem.

 
 
Pancreatic Cysts -- Part 2: Should We Be Less Cyst Centric?

  • Journal: Pancreas
  • Institution(s): The Johns Hopkins Medical Institutions, Baltimore, MD
  • Corresponding author(s): Anne Marie Lennon
  • Pancreatic Cancer Action Network-affiliated author: Marcia Canto, MD: co-PI, 2013 Skip Viragh – Inaugural Research Acceleration Network Grant and member, Emeritus Scientific & Medical Advisory Board
  • Major finding: In this article, the authors review the strengths and weaknesses of the American Gastroenterology Association guidelines, highlight key recommendations requiring further validation, and provide their balanced approach to diagnosing and managing pancreatic cysts.

 
 
The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells

  • Journal: Scientific Reports
  • Institution(s): Van Andel Research Institute, Grand Rapids, MI, and others
  • Corresponding author(s): Brian Haab
  • Pancreatic Cancer Action Network-affiliated author: Aatur Singhi, MD, PhD: recipient, 2016 Translational Research Grant
  • Major finding: The authors recently identified a carbohydrate antigen, named sTRA, that is as accurate a serological biomarker of pancreatic cancer as the cancer antigen CA19-9. The sTRA and CA19-9 glycans define separate subpopulations of cancer cells and could together have value for classifying subtypes of pancreatic adenocarcinoma.

 
 
Microscopic Lymphovascular Invasion Is an Independent Predictor of Survival in Resected Pancreatic Ductal Adenocarcinoma

  • Journal: Journal of Surgical Oncology
  • Institution(s): Thomas Jefferson University, Philadelphia, PA, and others
  • Corresponding author(s): Jordan Winter
  • Major finding: As the first large scale study focused on the clinical impact of lymphovascular invasion (LVI) status in pancreatic ductal adenocarcinoma, these data indicate that this routinely reported pathologic feature is a bona fide and independent adverse prognostic factor.

 
 
Preoperative Platelet Lymphocyte Ratio as Independent Predictors of Prognosis in Pancreatic Cancer: A Systematic Review and Meta-analysis

  • Journal: PLoS One
  • Institution(s): The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • Corresponding author(s): Shu-bing Zou
  • Major finding: MEDLINE, EMBASE, and Cochrane databases were searched to identify studies evaluating the prognostic significance of preoperative platelet lymphocyte ratio (PLR) in pancreatic cancer (PC). The preoperative PLR may be a significant independent prognostic factor in patients with PC.

 
 
Pretreatment C-reactive Protein to Albumin Ratio for Predicting Overall Survival in Advanced Pancreatic Cancer Patients

  • Journal: Scientific Reports
  • Institution(s): Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Corresponding author(s): Liwei Wang
  • Major finding: C-reactive protein to albumin ratio (CAR) was an independent prognostic factor for overall survival in the Cox regression model. Furthermore, the discrimination ability of CAR was slightly higher than that of other inflammation-based factors. Therefore, pretreatment CAR could be an independent prognostic biomarker for advanced pancreatic cancer patients.

 
 

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.






Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved.


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision PromiseSM and Demand Better For Patients. For Survival.SM are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.